Persistence on subcutaneous tocilizumab as monotherapy or in combination with synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients in Greece (EMBRACE study) : a multicenter, post-marketing, non-interventional, observational trial
© 2024. The Author(s)..
INTRODUCTION: Rheumatoid arthritis (RA) is a systemic, inflammatory disease affecting multiple organs and causing physical disability over time.
OBJECTIVE: The primary objective was to evaluate treatment persistence to subcutaneous tocilizumab (TCZ-SC). Additionally, treatment effects on persistence and their associations with clinical and patient-reported outcomes were assessed.
METHOD: We performed a multicenter, non-interventional, 52-week observational study on 222 patients with moderate or severe RA. Clinical outcomes were evaluated by using disease activity score for 28 joints (DAS28) and European League Against Rheumatism (EULAR) response, and patients' perceptions were evaluated by using Health Assessment Questionnaire (HAQ), Visual Analog Scale (VAS) for pain, and patient global assessment (PtGA) of disease activity. Safety was assessed throughout the study.
RESULTS: The mean age of the overall cohort was 62.2 ± 12.3 years, and 83.8% were females. Persistence to TCZ-SC was 89.6% at week 24 and 85.1% at week 52 in the overall cohort with slightly increased persistence in the combination group. At week 52, changes from the baseline were - 2.68 in DAS28, - 0.76 in HAQ, - 43.21 in VAS pain, and - 41.66 in PtGA (p < 0.0001 for all). Moderate and good EULAR response was achieved in 83.2% of patients. Non-serious and serious adverse events occurred in 18.5% and 3.2% of the participants, respectively.
CONCLUSIONS: The current study confirms the favorable safety and effectiveness of TCZ-SC as well as its acceptability by RA patients in Greece, with sustained high persistence rates up to 52 weeks. TCZ-SC offers a sustainable treatment response in RA. Key Points • Based upon clinical and patient-reported outcomes, TCZ-SC is a highly effective and safe treatment modality in patients with moderate-to-severe RA. • Persistence to TCZ-SC was high throughout the study, both as monotherapy and in combination with csDMARDs. • TCZ-SC is effective both as monotherapy and when used in combination with other csDMARDs regardless of the line of treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Clinical rheumatology - 43(2024), 5 vom: 02. Apr., Seite 1469-1478 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Athanassiou, Panagiotis [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10067-024-06916-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369622413 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369622413 | ||
| 003 | DE-627 | ||
| 005 | 20240425233131.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240313s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10067-024-06916-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM369622413 | ||
| 035 | |a (NLM)38472527 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Athanassiou, Panagiotis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Persistence on subcutaneous tocilizumab as monotherapy or in combination with synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients in Greece (EMBRACE study) |b a multicenter, post-marketing, non-interventional, observational trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a INTRODUCTION: Rheumatoid arthritis (RA) is a systemic, inflammatory disease affecting multiple organs and causing physical disability over time | ||
| 520 | |a OBJECTIVE: The primary objective was to evaluate treatment persistence to subcutaneous tocilizumab (TCZ-SC). Additionally, treatment effects on persistence and their associations with clinical and patient-reported outcomes were assessed | ||
| 520 | |a METHOD: We performed a multicenter, non-interventional, 52-week observational study on 222 patients with moderate or severe RA. Clinical outcomes were evaluated by using disease activity score for 28 joints (DAS28) and European League Against Rheumatism (EULAR) response, and patients' perceptions were evaluated by using Health Assessment Questionnaire (HAQ), Visual Analog Scale (VAS) for pain, and patient global assessment (PtGA) of disease activity. Safety was assessed throughout the study | ||
| 520 | |a RESULTS: The mean age of the overall cohort was 62.2 ± 12.3 years, and 83.8% were females. Persistence to TCZ-SC was 89.6% at week 24 and 85.1% at week 52 in the overall cohort with slightly increased persistence in the combination group. At week 52, changes from the baseline were - 2.68 in DAS28, - 0.76 in HAQ, - 43.21 in VAS pain, and - 41.66 in PtGA (p < 0.0001 for all). Moderate and good EULAR response was achieved in 83.2% of patients. Non-serious and serious adverse events occurred in 18.5% and 3.2% of the participants, respectively | ||
| 520 | |a CONCLUSIONS: The current study confirms the favorable safety and effectiveness of TCZ-SC as well as its acceptability by RA patients in Greece, with sustained high persistence rates up to 52 weeks. TCZ-SC offers a sustainable treatment response in RA. Key Points • Based upon clinical and patient-reported outcomes, TCZ-SC is a highly effective and safe treatment modality in patients with moderate-to-severe RA. • Persistence to TCZ-SC was high throughout the study, both as monotherapy and in combination with csDMARDs. • TCZ-SC is effective both as monotherapy and when used in combination with other csDMARDs regardless of the line of treatment | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biological therapies | |
| 650 | 4 | |a Medication persistence | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Subcutaneous injection | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Katsimbri, Pelagia |e verfasserin |4 aut | |
| 700 | 1 | |a Bounas, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Gazi, Sοusana |e verfasserin |4 aut | |
| 700 | 1 | |a Sarikoudis, Theodosios |e verfasserin |4 aut | |
| 700 | 1 | |a Syrigou, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Boumpas, Dimitrios |e verfasserin |4 aut | |
| 700 | 0 | |a EMBRACE Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Georgiadis, Athanasios |e investigator |4 oth | |
| 700 | 1 | |a Kallitsakis, Ioannis |e investigator |4 oth | |
| 700 | 1 | |a Kampakis, Georgios |e investigator |4 oth | |
| 700 | 1 | |a Kandyli, Anna |e investigator |4 oth | |
| 700 | 1 | |a Kotrotsios, Anastasios |e investigator |4 oth | |
| 700 | 1 | |a Koukli, Eftychia-Maria |e investigator |4 oth | |
| 700 | 1 | |a Ksirogiannis, Georgios |e investigator |4 oth | |
| 700 | 1 | |a Lagoudakis, Aristeidis |e investigator |4 oth | |
| 700 | 1 | |a Mavragani, Clio |e investigator |4 oth | |
| 700 | 1 | |a Mavridou, Dimitra |e investigator |4 oth | |
| 700 | 1 | |a Merantzis, Pavlos |e investigator |4 oth | |
| 700 | 1 | |a Natskos, Theodoros |e investigator |4 oth | |
| 700 | 1 | |a Papadimitriou, Georgios E |e investigator |4 oth | |
| 700 | 1 | |a Petrou, Dimitrios |e investigator |4 oth | |
| 700 | 1 | |a Psaltis, Dimitrios |e investigator |4 oth | |
| 700 | 1 | |a Tsiakou, Eleni |e investigator |4 oth | |
| 700 | 1 | |a Zakalka, Marina |e investigator |4 oth | |
| 700 | 1 | |a Ziogas, Athanasios |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d 1987 |g 43(2024), 5 vom: 02. Apr., Seite 1469-1478 |w (DE-627)NLM012613037 |x 1434-9949 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2024 |g number:5 |g day:02 |g month:04 |g pages:1469-1478 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10067-024-06916-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2024 |e 5 |b 02 |c 04 |h 1469-1478 | ||